Cargando…

Targeting Akt in cancer for precision therapy

Biomarkers-guided precision therapeutics has revolutionized the clinical development and administration of molecular-targeted anticancer agents. Tailored precision cancer therapy exhibits better response rate compared to unselective treatment. Protein kinases have critical roles in cell signaling, m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hua, Hui, Zhang, Hongying, Chen, Jingzhu, Wang, Jiao, Liu, Jieya, Jiang, Yangfu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379749/ https://www.ncbi.nlm.nih.gov/pubmed/34419139 http://dx.doi.org/10.1186/s13045-021-01137-8

Ejemplares similares

Targeting mTOR for cancer therapy
por: Hua, Hui, et al.
Publicado: (2019)

Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy
por: Jiang, Yangfu, et al.
Publicado: (2022)

Complex roles of cAMP–PKA–CREB signaling in cancer
por: Zhang, Hongying, et al.
Publicado: (2020)

Gamma synuclein promotes cancer metastasis through the MKK3/6-p38MAPK cascade
por: Liu, Jieya, et al.
Publicado: (2022)

Exploiting RIG-I-like receptor pathway for cancer immunotherapy
por: Jiang, Yangfu, et al.
Publicado: (2023)

Mechanisms for estrogen receptor expression in human cancer
por: Hua, Hui, et al.
Publicado: (2018)

Gamma synuclein is a novel Twist1 target that promotes TGF-β-induced cancer cell migration and invasion
por: Shao, Ting, et al.
Publicado: (2018)

Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy
por: Hua, Hui, et al.
Publicado: (2020)

Blockade of AMPK-Mediated cAMP–PKA–CREB/ATF1 Signaling Synergizes with Aspirin to Inhibit Hepatocellular Carcinoma
por: Zhang, Hongying, et al.
Publicado: (2021)

SEPHS1 promotes SMAD2/3/4 expression and hepatocellular carcinoma cells invasion
por: Yang, Shu, et al.
Publicado: (2021)

Synergistic promotion of breast cancer cells death by targeting molecular chaperone GRP78 and heat shock protein 70
por: Li, Minjing, et al.
Publicado: (2009)

Derlin-1 is overexpressed in human breast carcinoma and protects cancer cells from endoplasmic reticulum stress-induced apoptosis
por: Wang, Jiao, et al.
Publicado: (2008)

Signaling pathways and targeted therapy for myocardial infarction
por: Zhang, Qing, et al.
Publicado: (2022)

PCAT6 May Be a Whistler and Checkpoint Target for Precision Therapy in Human Cancers
por: Jiang, Feng, et al.
Publicado: (2021)

AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin
por: Gao, Mei, et al.
Publicado: (2016)

Targeted Therapies and Developing Precision Medicine in Gastric Cancer
por: Pihlak, Rille, et al.
Publicado: (2023)

Roles of DNA damage repair and precise targeted therapy in renal cancer (Review)
por: Lai, Yongchang, et al.
Publicado: (2022)

Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy
por: Ding, Xiao-Xiao, et al.
Publicado: (2017)

Targeting PI3K/Akt signal transduction for cancer therapy
por: He, Yan, et al.
Publicado: (2021)

(-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma
por: Luo, Ting, et al.
Publicado: (2010)

Blockade of GRP78 sensitizes breast cancer cells to microtubules-interfering agents that induce the unfolded protein response
por: Wang, Jiao, et al.
Publicado: (2009)

Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy——AKT/m-TOR Pathway and Resistance to Cancer Therapy
por: SPIRINA, Liudmila V, et al.
Publicado: (2018)

Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy
por: Patel, Shruti R., et al.
Publicado: (2023)

Proton beam therapy for cancer in the era of precision medicine
por: Hu, Man, et al.
Publicado: (2018)

The natural agent rhein induces β‐catenin degradation and tumour growth arrest
por: Liu, Shu, et al.
Publicado: (2017)

Precision Targets for Intercepting the Lethal Progression of Prostate Cancer: Potential Avenues for Personalized Therapy
por: Christenson, Max, et al.
Publicado: (2022)

Smart drug delivery systems for precise cancer therapy
por: Wang, Xiaoyou, et al.
Publicado: (2022)

Recent Advances in Zein-Based Nanocarriers for Precise Cancer Therapy
por: Huang, Wenquan, et al.
Publicado: (2023)

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
por: Zhu, Kunrui, et al.
Publicado: (2022)

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
por: Li, Xiaoman, et al.
Publicado: (2016)

Role of Akt signaling in resistance to DNA-targeted therapy
por: Avan, Abolfazl, et al.
Publicado: (2016)

Reprogramming the tumor microenvironment by genome editing for precision cancer therapy
por: Liu, Ke, et al.
Publicado: (2022)

Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies
por: Phan, Liem Minh, et al.
Publicado: (2014)

Biomarkers in precision therapy in colorectal cancer
por: Reimers, Marlies S., et al.
Publicado: (2013)

Molecular profiling for precision cancer therapies
por: Malone, Eoghan R., et al.
Publicado: (2020)

Circulating tumor cells in prostate cancer: Precision diagnosis and therapy
por: Liu, Weiwei, et al.
Publicado: (2017)

Precision Oncology Targets in Biliary Tract Cancer
por: Farha, Nicole, et al.
Publicado: (2023)

Molecular target: pan-AKT in gastric cancer
por: Kang, Byung Woog, et al.
Publicado: (2020)

Breast cancer heterogeneity and its implication in personalized precision therapy
por: Guo, Liantao, et al.
Publicado: (2023)

Aflatoxin B1 Up-Regulates Insulin Receptor Substrate 2 and Stimulates Hepatoma Cell Migration
por: Ma, Yanli, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_itmrtb91heuboa9bl86noruofl